Management Team

Tarig Bashir

PhD – CEO

 

Tarig Bashir, PhD, joined FoRx Therapeutics as CEO in April 2021. He is a Pharma and Biotech Executive with over 15 years of experience and leadership in cancer drug discovery, translational oncology and external innovation. During his career, he has led and overseen discovery-stage and preclinical oncology portfolios, led strategic partnerships with pharma and academia, and contributed significantly to clinical compound development. Tarig held positions of increasing responsibility in Oncology R&D at Organon/Schering-Plough, Johnson & Johnson and Ipsen. Most recently he was Executive Vice President Discovery at Proteros, where his responsibilities included new company building.    

Read more

Tarig studied biology at the University of Würzburg and the State University of New York at Albany. He earned his PhD at the German Cancer Research Center (DKFZ) in Heidelberg and conducted his postdoctoral training at the New York University School of Medicine.

Colin Goddard

PhD – Chairman of the Board

 

Dr. Goddard is actively involved in the Biotechnology industry as a board director and
executive. He works as an investor and board member in a number of early stage and
public biotechnology companies, leveraging over 30 years of experience in the industry. From October 1998, until it’s $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc. a company he joined as a scientist in 1989. In this role he raised over $1.5 billion and oversaw the development, approval and commercial launch of Tarceva®, a leading lung cancer medicine.

Read more

He is Chairman of the board of Mission Therapeutics, and a board member at Hibercell, Inc., Ryvu Therapeutics and BlinkBio, Inc. He has been active in many organizations that support cancer research and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in 1985 and conducted his post-doctoral research at the National Cancer Institute in Bethesda, MD.

Ulrich Lücking

PhD – Head of Chemistry

 

Ulrich Lücking, PhD, is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his path Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.

Read more

Prior to joining industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr,  and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.

Sotirios K. Sotiriou

PhD – Head of Biology

 

Sotirios Sotiriou, PhD, is a Molecular Cancer Biologist currently working as the Head of Biology at FoRx Therapeutics. Previously, he worked as a postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School, Broad Institute of MIT and Harvard and University of Geneva. Sotirios received his PhD degree with great distinction in Molecular Biology from the University of Geneva.

Read more

Sotirios completed his undergraduate studies in Biological Applications and Technology at the University of Ioannina. His research interests focus on DNA repair, DNA replication, and the mechanisms underlying genomic instability in human cancers.